Research advances in the application of antiviral drugs during pregnancy for blocking mother-to-child transmission of hepatitis B virus
10.3969/j.issn.1001-5256.2018.10.032
- VernacularTitle:孕期服用抗病毒药物阻断HBV母婴传播的研究进展
- Author:
Huijuan WANG
1
;
Zhongping DUAN
;
Huanhu ZHANG
Author Information
1. Department of Gastroenterology, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan 030001, China
- Publication Type:Research Article
- Keywords:
hepatitis B virus;
disease transmission, vertical;
antiviral agents;
review
- From:
Journal of Clinical Hepatology
2018;34(10):2208-2212
- CountryChina
- Language:Chinese
-
Abstract:
Mother-to-child vertical transmission is an important route of transmission for hepatitis B virus (HBV) infection in patients with chronic hepatitis B, and the rate of HBV infection increases with the increase in the mother′s HBV viral load. Although active and passive immunoprophylaxis has been implemented for neonates at present, the rate of mother-to-child vertical transmission of HBV remains around 10%. Therefore, pregnant women with a high viral load should receive antiviral therapy to reduce the viral load, in order to prevent and block the mother-to-child transmission of HBV and reduce the incidence rate of chronic hepatitis B. By retrieving related literature in China and foreign countries, this article describes the safety and efficacy of antiviral agents during pregnancy and provides a reliable basis for guiding medication during pregnancy.
